OBLITERIDE
SAVE THE DATE:
AUGUST 7 – 8, 2020
info@obliteride.org
206.667.RIDE (7433)
LEARN MORE

Fred Hutchinson Cancer Research Center works at the leading edge of science to discover and accelerate lifesaving prevention, treatments, and cures for cancer, HIV, and other diseases that affect humanity. Learn more at fredhutch.org.

OBLITERIDE: 2019 YEAR IN REVIEW
CURE CANCER FASTER

© Fred Hutchinson Cancer Research Center, 2020. All rights reserved. The Obliteride name is a registered trademark of Fred Hutchinson Cancer Research Center.
WOW! OBLITERIDE 2019 WAS AN INSPIRING WEEKEND OF JOY, HEART, AND DETERMINATION.

Thank you for being part of our big orange community.

We have so much to celebrate! Together, our participants and sponsors raised an amazing $4 million in 2019. This is our largest fundraising amount ever and an achievement that brings our seven-year total to an astounding $28.8 million. And, thanks to our sponsors, 100% of participant-raised funds have gone right to work: helping scientists drive science forward to prevent, treat, and cure cancer and other diseases.

This year, our community continued to grow. We welcomed a record-breaking 2,453 participants, nearly 600 volunteers, more than 17,000 donors, and hundreds of partners and supporters. In addition, our incredible teams continued to build camaraderie and friendships and show the world what team spirit looks like. Thank you for leading the way. Together, we have made Obliteride the largest and best-organized fundraising event of its kind in the Pacific Northwest.

We are gearing up for some changes in 2020 as we welcome our new Obliteride director, Jim Birrell. Jim was co-owner of Medalist Sports, the logistics production event company that has partnered with Fred Hutch to produce Obliteride since the event began in 2013. As a member of the family since Obliteride’s inception, Jim brings an insider’s deep knowledge along with extensive leadership experience and countless ideas about how we can take the event to the next level.

And we’re excited about our new Obliteride website. This beautiful resource makes it even easier to participate in Obliteride and raise funds for Fred Hutch.

As I think about Obliteride weekend 2019, so many moments stand out. Dancing at our Friday Night party to the rousing music of Rainbow Kitten Surprise. Cheering and high-fiving in the rainy dawn as our bikers set out, ready as ever. And, as the rain gave way to bright sun, cheering with volunteers and friends as our riders, walkers, and runners crossed the finish line at Gas Works Park.

Throughout it all, our community was an unstoppable force: Embracing summer, coming together to honor everyone who has faced cancer, and raising funds for breakthrough research at Fred Hutch.

Year after year, our participants tell us that the best part of Obliteride is the people.

Year over year, our participants tell us that the best part of Obliteride is the people.
LEASE CRUTCHER LEWIS: “As a longtime business partner of the Hutch, Lease Crutcher Lewis is close witness to amazing discoveries, therapies, and cures. Our employee-owners are thrilled to support Fred Hutch’s important work as seven-time Obliteride participants. We’re proud of the Lewis and Friends team for being a top fundraiser.” — Jeff Cleator, President, Lease Crutcher Lewis

ADAPTIVE BIOTECHNOLOGIES: “Private funding is critical to advancing innovative research. Adaptive benefited from private funding to the Hutch in our early days. And we are now proud to make this type of funding available to other researchers. By supporting Obliteride, we are helping to cure cancer faster.” — Chad Robins, Co-Founder & CEO, Adaptive Biotechnologies

GLY: “Since we believe community leadership comes from within, GLY employees are empowered to help choose which nonprofits we support. Cancer touches everyone, and has certainly impacted GLY. Our culture values hard work, and we support Fred Hutch’s relentless effort to find a cure.” — Ted Herb, President & CEO, GLY

SAFEWAY ALBERTSONS: “Safeway Albertsons is proud to support Fred Hutch and Obliteride because it’s an extraordinary day when all in the region who have been impacted by cancer can join together to say thank you to the dedicated researchers at the Hutch who are working to accelerate cures.” — Sara Osborne, External Affairs Director for the Seattle Division of Safeway Inc. and Albertsons

AMAZON: “Amazon and Fred Hutch are founded on being bold, promoting big ideas, and taking risks. We’re creative, we’re innovators. Now, more than ever, we need to work together to end cancer once and for all. That’s why Amazon is all in for Obliteride.” — Jarman Hauser, EC2 Spot Research & Discovery, AWS

DOCUSIGN: “DocuSign is deeply committed to having a positive impact in and on our communities. We like to get involved in causes that match our employees’ interests and talents. Obliteride is a wonderful event where we can be all-in on such an important cause.” — Dan Springer, CEO, DocuSign

WHY WE OBLITERIDE

Obliteride unites people around a common mission and is fueled by a shared passion — to CURE CANCER FASTER. We rally in support of others — family, friends or colleagues — or to celebrate or commemorate a personal experience with the disease. This powerful convergence of community and caring is what Obliteride is all about — together we ride, walk, run, and volunteer in hopes of saving lives and making a difference.
RIDERS 1779
FIRST-TIME RIDERS 803
RETURNING RIDERS 976

WALKERS 572
WALKERS UNDER 18 102

MALE 52%
FEMALE 44%
UNDisclosed 4%

2025 CREW
262 Raised
OVER $2,000

67 RAISED $5,000 OR MORE

590 Volunteers
328 People
Pre-registered for Obliteride 2020!

34 STATES REPRESENTED
2 INTERNATIONAL PARTICIPANTS

175 SURVIVORS (SELF-REPORTED)

1003 VOLUNTEER HOURS

WE ARE OBLITERIDE 2019

34
2
34 STATES REPRESENTED
INTERNATIONAL PARTICIPANTS

FRED HUTCH OBLITERIDE
**2019 PARTICIPANTS**

**BY THE NUMBERS**

**CYCLIST TYPE**

- 11% CREATIONAL CYCLIST
- 45% AVI D CYCLIST
- 40% CYCLIST ONLY
- 3% SOCIAL OBLITERIDE

**WALKER/RUNNER TYPE**

- 11% AVID WALKER
- 32% AVID RUNNER
- 27% WALKER/RUNNER
- 30% SOCIAL STROLLER
- 14% SOCIO-RECREATIONAL WALKER/RUNNER

**PARTICIPANT BREAKDOWN**

- 86% RIDE
- 14% WALK/RUN

**WHAT IS YOUR INSPIRATION TO RIDE?**

- Support or honoring others: 76%
- Support Fred Hutch: 69%
- Personal fitness challenge: 36%
- Part of a work team: 33%
- Have fun with friends: 18%
- I am a survivor: 18%
- Encouraged by friends: 11%
- Do something new: 9%
- Watched in the past: 2%

**WHAT KEEPS YOU COMING BACK TO OBLITERIDE?**

- The mission: 76%
- The energy: 48%
- It’s a tradition: 34%
- Community with my team: 28%
- Cure cancer faster: 24%
- Other: 17%
- Stay in shape: 14%

**ANNUAL HOUSEHOLD INCOME**

- $100K - $150K: 28%
- $150K - $275K: 23%
- More than $275K: 18%
- Prefer not to answer: 16%
- $50K - $100K: 15%
- Less than $50K: 3%

**HIGHEST LEVEL OF EDUCATION COMPLETED**

- Bachelor’s degree: 50%
- Master’s degree: 26%
- Doctoral or professional degree: 14%
- Two or more years of college: 3%

**2019 FUNDRAISERS**

**TOP FUNDRAISERS**

*Total 2019 fundraising Over $4 Million*

**TOP 10 FUNDRAISING INDIVIDUALS**

<table>
<thead>
<tr>
<th>NAME</th>
<th>ROUTE</th>
<th>TEAM</th>
<th>DONATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jake &amp; Joe Shleifer</td>
<td>Virtual Obliterider</td>
<td>Jake &amp; Joe Take Over Team Jerry Jaffe</td>
<td>$66,832</td>
</tr>
<tr>
<td>Paula Reynolds</td>
<td>50-Mile Rider</td>
<td>CureCyclists</td>
<td>$53,401</td>
</tr>
<tr>
<td>Molly Nordstrom</td>
<td>5K Walk/Run</td>
<td>CureCyclists</td>
<td>$48,500</td>
</tr>
<tr>
<td>Chad Robins</td>
<td>50-Mile Rider</td>
<td>Adaptive Biotechnologies</td>
<td>$48,074</td>
</tr>
<tr>
<td>Julie Nordstrom</td>
<td>50-Mile Rider</td>
<td>CureCyclists</td>
<td>$42,225</td>
</tr>
<tr>
<td>Mark Fleischauer</td>
<td>100-Mile Rider</td>
<td>Team JHKelly</td>
<td>$38,900</td>
</tr>
<tr>
<td>Erik Nordstrom</td>
<td>50-Mile Rider</td>
<td>CureCyclists</td>
<td>$37,960</td>
</tr>
<tr>
<td>Richard Kaplan</td>
<td>25-Mile Rider</td>
<td>Microsoft &amp; Friends</td>
<td>$35,400</td>
</tr>
<tr>
<td>Peter Nelson</td>
<td>100-Mile Rider</td>
<td>Early Bird Team iPCr</td>
<td>$28,865</td>
</tr>
<tr>
<td>David Powell</td>
<td>25-Mile Rider</td>
<td>Microsoft &amp; Friends</td>
<td>$23,340</td>
</tr>
</tbody>
</table>

**TOP 10 FUNDRAISING TEAMS**

<table>
<thead>
<tr>
<th>TEAM</th>
<th>TEAM CAPTAIN</th>
<th>PARTICIPANTS</th>
<th>DONATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cure Cyclists</td>
<td>Dave Kolk</td>
<td>69</td>
<td>$271,864</td>
</tr>
<tr>
<td>Microsoft &amp; Friends</td>
<td>David Powell</td>
<td>112</td>
<td>$226,713</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>Charles Linkem &amp; Kellie Howard</td>
<td>117</td>
<td>$148,385</td>
</tr>
<tr>
<td>Amazon</td>
<td>Shannon O’Fallon</td>
<td>158</td>
<td>$103,130</td>
</tr>
<tr>
<td>LEWIS &amp; FRIENDS</td>
<td>Tyler Thornton</td>
<td>65</td>
<td>$57,326</td>
</tr>
<tr>
<td>Team JHKelly</td>
<td>Mark Fleischauer</td>
<td>26</td>
<td>$79,987</td>
</tr>
<tr>
<td>Team Bheem</td>
<td>Tonia Goyal</td>
<td>50</td>
<td>$70,656</td>
</tr>
<tr>
<td>Jake &amp; Joe Take Over Team Jerry Jaffe</td>
<td>Jake &amp; Joe Shleifer</td>
<td>2</td>
<td>$68,014</td>
</tr>
<tr>
<td>Team iPCr</td>
<td>Peter Nelson</td>
<td>26</td>
<td>$55,248</td>
</tr>
<tr>
<td>Fizards Forever</td>
<td>Kristi Sullivan</td>
<td>58</td>
<td>$52,495</td>
</tr>
</tbody>
</table>

**2019 PARTICIPANTS**

**2019 YEAR IN REVIEW**

**ANNUAL HOUSEHOLD INCOME**

- $100K – $150K: 28%
- $150K – $275K: 23%
- More than $275K: 18%
- Prefer not to answer: 16%
- $50K – $100K: 15%
- Less than $50K: 3%

**HIGHEST LEVEL OF EDUCATION COMPLETED**

- Bachelor’s degree: 50%
- Master’s degree: 26%
- Doctoral or professional degree: 14%
- Two or more years of college: 3%
WHERE THE MONEY GOES

Obliteride funds urgent research across Fred Hutch, from basic science and public health to immunotherapy and deep exploration into organ-specific cancers. Obliteride supports many areas of research, including:

**BRAIN CANCER**
Tumor Paint helps surgeons distinguish between the tumor and healthy brain cells, allowing for complete and precise removal of the tumor.

**BREAST CANCER**
Fred Hutch researchers are reducing breast cancer incidence and impact by identifying risk factors, developing new methods of detecting its presence, and helping to predict health outcomes based on genetics and other factors.

**CLINICAL RESEARCH**
Our groundbreaking clinical trials are providing patients with new cures.

**ENVIRONMENT**
We’re learning how environmental exposure, lifestyle choices, and access to health care and community services all impact the incidence of cancer.

**IMMUNOTHERAPY**
We are finding new ways to harness patients’ own immune systems to fight their cancers. Accelerating this research is vital to curing cancer faster.

**INFECTION**
More than 1 in 5 cancers worldwide are caused by infections. Research at Fred Hutch paved the way for the HPV vaccine, which has the potential to eradicate nearly all cervical cancer and many head and neck cancers. If we can prevent infections, we can avoid some cancers altogether.

**LUNG CANCER**
We are gaining a deeper understanding of how genetic factors influence lung cancer in smokers and non-smokers to provide more targeted treatments.

**OVARIAN CANCER**
Better detection, understanding, and treatment are all critical to increasing survival rates for patients with ovarian cancer.

**PROSTATE CANCER**
Fred Hutch investigators recently published research linking BRCA mutations with metastatic prostate cancer, helping us identify those more at risk.

**TUMOR RESEARCH**
Our researchers are moving lab theory, data models, and tissue typing from the lab to the bedside as rapidly as possible.

Fred Hutch researchers powered by Obliteride

**DR. ALICE BERGER**  •  Human Biology & Public Health Sciences Divisions
Dr. Alice Berger is an expert in discovering how changes to our genetic code lead to cancer. Deep examinations of the genetic code in tumors highlight many mutations — or typos in the DNA sequence — but it’s not always clear what specific consequences these mutations will have. Known as “variants of unknown significance,” these mutations are part of why the picture of cancer is so complex. Alice is working to uncomplicate this picture and has developed a technique to evaluate, in one go, how hundreds of variants of unknown significance influence the function of the proteins encoded by their genes. This is the first step toward determining whether a particular genetic typo promotes cancer development. She and her team are working to translate these insights into new drug targets and biomarkers to benefit patients. Alice holds the Innovators Network Endowed Chair.

**DR. SUE BIGGINS**  •  Basic Sciences Division
Dr. Sue Biggins leads Fred Hutch’s Basic Sciences Division, where she studies how cells divide and distribute their chromosomes, a process that is almost always disrupted in cancer. The major structure involved in maintaining the precision of this process is the kinetochore, but understanding its functionality has eluded scientists. Sue and her team devised a new technique, which resulted in the first close-up pictures of an assembled kinetochore. Because these structures play such a significant role in chromosome segregation, her findings could have important implications for treating cancer. If research leads to drugs that stop kinetochores from doing their job in unhealthy cells, they would be unable to divide and propagate at all, stopping a disease such as cancer.

**DR. MARK HEADLEY**  •  Clinical Research Division
Dr. Mark Headley studies how immune cells can be both friend and foe during metastasis, when cancer cells spread from a primary tumor to distant organs. Some immune cells work hard to detect and defend against cancer. But others actively serve the tumor, helping it survive and thrive. Focusing specifically on metastatic tumors that arise in the lung, Mark and his team use sophisticated tools, such as advanced microscopes and surgical techniques, to zero in on the earliest moments of metastasis, when a “small scrum” of immune cells are interacting with perhaps just one metastatic tumor cell. Mark’s research could lay the groundwork for a new class of therapies that boost the immune system’s innate ability to battle metastasis — and block its traitorous tendencies.

**DR. CHRISTOPHER JOHNSTON**  •  Vaccine & Infectious Disease Division
Dr. Christopher Johnston is a microbiologist who studies the trillions of bacteria that live on us and within us. While most of these species are harmless or even beneficial, some are implicated in oral and lung infections, cardiovascular disease, and cancer. Christopher specializes in bacteria that inhabit the mouth and the gut and has designed new genetic engineering approaches to modify bacteria. It is surprisingly difficult to engineer the genes of simple bacteria because they have evolved over billions of years and developed sophisticated barriers. Christopher’s new tool allows swift and efficient genetic manipulation, which is helping his lab and researchers around the world uncover how bacteria behave during infection, how they acquire resistance to antibiotics, and how they can be engineered to produce molecules for human use.

VISIT OBILTERIDE.ORG TO LEARN MORE ABOUT THE IMPACT OF YOUR SUPPORT.
FRED HUTCH OBLITERIDE
THANKS OUR GENEROUS SPONSORS, PARTNERS & FRIENDS

LEAD OUT SPONSOR
UNIVERSITY VILLAGE

FOUNDING SPONSOR
SLOAN FOUNDATION

CENTURY SPONSORS
amazon  SAFEWAY  SINEGAL FOUNDATION

BREAKAWAY SPONSORS

dynamo SPONSORS

REST STOP SPONSORS

HOSPITALITY SPONSORS
1/4 Hands  Chateau Ste. Michelle  MERF  Nuun  Rachel's Ginger Beer  Talking Rain  Willamette Valley Vineyards

FRIENDS OF OBLITERIDE
Fremont Chamber of Commerce  Microsoft  Pacific Market International  Pedal Anywhere  Vulcan